- Authors of report
- Abd-Elrahman Said Hassan, Yimeng Lina Du, Su Yeon Lee, Aijun Wang, Diana Lee Farmer
- Date of report
- Medical conditions
- Spina Bifida
- Definition and Prevalence: Spina bifida is recognized as the most common congenital defect of the central nervous system. Individuals with this condition can face lifelong disabilities.
- Genetic and Molecular Understanding: Although the complete causes and mechanisms behind spina bifida are not yet fully grasped, there have been significant strides in understanding its genetic and molecular foundations.
- Treatment Evolution: The treatment methodologies for spina bifida have seen considerable progress over the years. Initially, the primary treatment was the surgical closure of the defect post-birth. However, medical advancements have now led to the development of intrauterine repair, which is considered state-of-the-art.
- Review Focus: The report delves into various aspects of spina bifida, including its genetics, embryology, and pathophysiology. It also discusses the current therapeutic approaches available for the condition.
- Emerging Therapies: One of the most notable highlights of the report is the mention of the first FDA-approved clinical trial that explores the use of stem cells as a potential treatment for spina bifida.
- Keywords: The report emphasizes certain keywords related to the topic, such as fetal surgery, pediatric surgery, and stem cells.
- Conflict of Interest: The authors of the report have declared that they have no conflicts of interest, ensuring the unbiased nature of the findings and discussions.
This is a summary of independent research published elsewhere. It is not a report of Beike treatment outcomes.
